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Abstract
Background:  The master regulator p53 tumor-suppressor protein through coordination of
several downstream target genes and upstream transcription factors controls many pathways
important for tumor suppression. While it has been reported that some of the p53's functions are
microRNA-mediated, it is not known as to how many other microRNAs might contribute to the
p53-mediated tumorigenesis.
Results: Here, we use bioinformatics-based integrative approach to identify and prioritize putative
p53-regulated miRNAs, and unravel the miRNA-based microregulation of the p53 master
regulatory network. Specifically, we identify putative microRNA regulators of a) transcription
factors that are upstream or downstream to p53 and b) p53 interactants. The putative p53-miRs
and their targets are prioritized using current knowledge of cancer biology and literature-reported
cancer-miRNAs.
Conclusion:  Our predicted p53-miRNA-gene networks strongly suggest that coordinated
transcriptional and p53-miR  mediated networks could be integral to tumorigenesis and the
underlying processes and pathways.
Background
The p53 tumor suppressor gene has been implicated as a
master regulator of genomic stability, cell cycle, apoptosis,
and DNA repair [1,2]. p53 is known to act as both tran-
scriptional activator and repressor of expression of specific
genes [3]. Studies of p53-mediated repression have shown
that both genes that modulate apoptotic responses and
genes that promote cell cycle progression can be repressed
by p53 [4].
MicroRNAs (miRNAs or miRs) are small non-coding
RNAs typically of 21–25 nucleotides in length and
reported to be involved in the regulation of a variety of
biological processes, including development, cell death,
cell proliferation, hematopoiesis and nervous systems
patterning [5]. miRNAs enforce posttranscriptional silenc-
ing through the RNA interference pathway [6]. Currently
more than 450 human miRNAs have been identified and
deposited in the miRBase [7]. Computational prediction
of miRNA targets reveal that each human miRNA can
potentially target several genes [8,9], underscoring the
importance of these tiny noncoding RNAs in gene regula-
tion.
Several previous studies have identified ten positive or
negative feedback loops in the p53 pathway (reviewed in
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[10]). All of these networks or circuits are autoregulatory
in that they are either induced by p53 activity at the tran-
scriptional level, transcriptionally repressed by p53 or are
regulated by p53-induced proteins [10]. Recently, five
independent studies have shown that p53 upregulates
miR-34a in response to DNA damage leading to cell cycle
arrest and apoptosis [11-15]. In light of these reports and
based on the growing evidence that microRNAs them-
selves act to either promote cancer or to stop cancer spread
[16-19], it is reasonable to conceive that the tumor sup-
pressor p53 might be involved in this microRNA-related
network in cancer cells. In support of this, two miRNAs
(miR-372 and miR-373) were found to function as onco-
genes in human testicular germ cell tumors, probably by
numbing the p53 pathway and thereby allowing tumori-
genesis [20]. Yang et al recently suggested that analysis of
microRNA regulation in the transcriptional network of
the p53 gene can reveal relationships between oncogenic
microRNAs and p53 [21]. We therefore sought to explore
if there are other microRNAs that are components of the
p53 regulatory network. In an earlier study (Kaimal and
Sinha et al., unpublished), scanning the 474 human miR-
NAs for putative p53 sites, we identified 143 miRNAs that
have at least one p53 site (using p53MH algorithm [22])
and are predicted to target at least one known gene. We
termed these 143 miRNAs as p53-miRs (Kaimal and Sinha
et al., unpublished). In the current study, apart from cor-
relating these putative p53-miRs with the upstream regula-
tors and downstream targets of p53, we prioritize our
predictions using (a) literature reported differentially
expressed miRNAs in cancer; (b) miRNAs reported as
induced or repressed following p53 activation [11]; and
(c) miRNA targets that are functionally enriched with bio-
logical processes like apoptosis, cell cycle.
Results and discussion
Prediction of p53-miRs and the target genes
A significant fraction of human intergenic miRNAs are
reported to possess TSS sites within 2 kb of the pre-miRNA
[23]. Although it is accepted that intronic miRNAs are
generally transcribed along with their host genes [24], TSS
predictions have shown them to lie predominantly in the
region from -2 kb to -6 kb [23]. Hence, we limited our
search space to 10 kb flanking regions of the miRNAs.
Determination of exact pri-miRNA transcript lengths
however is possible only through experimental work.
We used p53MH [22], an algorithm that identifies p53-
responsive genes in the human and mouse genome, to
identify putative p53-binding site within miRNAs (see
Methods). Out of 474 human miRNAs analyzed, 227 had
at least one putative p53 site (and a total of 319 p53 sites;
some miRNAs have multiple p53 sites) within their flank-
ing regions of 10 kb (Additional File 1). Of the 319 p53
sites, 5 sites were overlapping with exonic region and we
did not consider these for further analysis. The 314 p53
sites (Additional File 2) occur within 10 kb flanking
sequences of 223 miRNAs. We identified two p53 binding
sites in mir-34a; however neither of these corresponds to
the experimental validated p53 site [12] in mir-34a. This
is because in the current analysis we limit the miRNA
flanking sequence search space to 10 kb only while the
experimentally validated p53 site in mir-34a occurs at
approximately 30 kb upstream to mir-34a [12].
To predict target genes of the 223 miRNAs, we used MAMI
server [25], which has compilation of five [8,9,26-28] tar-
get prediction algorithms. A recent study showed that
about 82% of unique miRNA-target pairs are predicted by
only a single algorithm [19]. Therefore, a combination of
predictions from all algorithms might provide a much
more comprehensive list of putative miRNA-target pairs
than do any single prediction. 154/223 miRNAs are pre-
dicted to target at least one gene while 69/223 have no
predicted targets. The 154 miRNAs mapped to 143 miR-
NAs. This is because some of the miRNAs have more than
one predicted hairpin precursor sequences. For example
mir-135a has two predicted hairpin precursors (mir-135a-
1 on chromosome 3 and mir-135a-2 on chromosome 12).
The targets are however based on mir-135a only. Thus,
our final set consists of 143 miRNAs; each of which has at
least one p53 site and is predicted to target at least one
known gene. We call these 143 miRNAs as p53-miRs.
There were 12497 genes predicted as targets of these 143
p53-miRs! Assuming that most of these predicted targets
are purely speculative (false positive rate of at least 4 of
these algorithms was estimated to be 20–30% [29]), we
sought to integrate multiple types of data resources and
explore as to what number of p53-miRs could be targeting
cancer-related genes.
MicroRNAs associated with p53 upstream and 
downstream genes
Transcriptional networks commonly contain positive-
and negative-feedback loops, which provide robustness
and fine-tuning to gene programs [30,31]. Recent studies
have suggested a possible coordinated transcriptional and
miRNA-mediated regulation as a recurrent motif to
enhance the robustness of gene regulation in mammalian
genomes [32-35]. It was also reported that miRNAs pre-
dominantly target positive regulatory motifs, highly con-
nected scaffolds and most downstream network
components such as signaling transcription factors, but
less frequently target negative regulatory motifs, common
components of basic cellular machines and most
upstream network components such as ligands [32].
Using the p53 master regulatory network as a case study,
we investigated the potential crosstalk between the miR-
NAs and the p53 transcriptional network itself involving
transcription factors upstream and downstream to p53. AtBMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
Page 3 of 19
(page number not for citation purposes)
least four possible scenarios can be envisaged for the
upstream regulators (Figures 1A–D) and downstream tar-
gets (Figures 1E–H) of p53.
We downloaded the known upstream transcription factor
(TF) regulators and downstream target TFs of p53 from
the p53 KnowledgeBase [36]. For the 23 upstream regula-
tors and 48 downstream TFs of p53, we then extracted the
putative miRNA regulators using MAMI server [25], which
has compilation of five target prediction algorithms
[8,9,26-28]. Since each of these five miRNA target predic-
tion approaches generates an unpredictable number of
false positives (an estimate puts it at 20–30% [29]), we
intersected the results to identify the genes commonly
predicted by at least two of the five algorithms [8,9,26-28]
(see Table 1; for a complete list, see Additional file 3).
Although it is important to confirm that a miRNA is not a
potential regulatory miRNA of a specific gene by using dif-
ferent bioinformatics algorithms [37], there are several
experimentally validated microRNA target genes that are
not predicted by more than one of the current prediction
algorithms. For instance the experimentally validated mir-
21-PTEN miRNA-target pair [38] is not predicted by any
of the five algorithms (listed in Methods and used in
MAMI compilation). To overcome this, we also checked
the TarBase [39] which has experimentally validated
microRNA targets irrespective of the computational pre-
dictions.
Based on MAMI predictions, a total of 242 different miR-
NAs suppress p53 regulators or targets. Of these, 115
(~48%) are p53-miRs (Figure 2A). Some of the p53-miRs
(32/143; Figure 2B) are found to exclusively target p53
upstream activators (13/143 p53-miRs; Figure 3A) or
repressors (5/143; Figure 3B) or downstream activators
(9/143; Figure 3C) or repressors (5/143; Figure 3D). Inter-
estingly, many of these miRNAs have been reported as dif-
ferentially expressed in various cancerous tissues or cell
lines (see last column in Table 1).
miRNAs upstream and downstream to p53: coherent and 
incoherent circuits
If there is a common upstream TF that regulates both the
miRNA and its target gene, ideally, the transcription of the
miRNAs and their targets should be oppositely regulated
by this common upstream TF. For example, p53 which is
known to repress the transcription of IER3  [40] may
simultaneously activate the transcription of mir-142 (pre-
dicted to target IER3) that may further inhibit IER3 post-
transcriptionally. This is a coherent model for all
downstream targets that are repressed by p53. Previous
genome-scale studies have in fact shown that predicted
target transcripts of several tissue-specific miRNAs tend to
be expressed at a lower level in tissues where the miRNAs
are expressed [41,42].
Alternately, a common TF (p53 in this case) can activate a
downstream target gene and also a miRNA which then
suppresses the downstream target gene. A well known
example is the experimentally confirmed microregulatory
network comprising miR-17-5p and E2F1 – both of which
are transcriptionally activated by c-Myc in human cells
[43]. We report a similar example of mir-122a, a putative
p53-miR suppressing CCNG1, a downstream target of p53.
CCNG1 is a known transcriptional target (activator) of the
p53 tumor suppressor protein [44] and it was recently
reported that mir-122a (predicted as p53-miR in our anal-
Four possible scenarios for the upstream regulators (A-D)  and downstream targets (E-H) of p53 Figure 1
Four possible scenarios for the upstream regulators (A-D) 
and downstream targets (E-H) of p53. For the downstream 
coherent models, the p53 action on downstream target gene 
and miRNA is opposite (F and H). In case of downstream 
incoherent models (E and G), the p53 action on downstream 
target gene and miRNA is same. There may be a sequential 
gap in the activation time of the target gene and miRNA facil-
itating maintenance of steady states.BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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ysis) has an inverse correlation with cyclin G1 expression
in primary liver carcinomas [45]. In other words, p53 acti-
vates CCNG1 and also mir-122a which in turn suppresses
CCNG1. This is an incoherent model. Adding to this com-
plexity further, it is also reported that CCNG1 negatively
regulates the stabilization of p53 in a possible negative
feedback loop [46] (Figure 4A). Thus, the regulatory net-
work wherein p53 activates a downstream target and a
miR (which target the downstream target) simultaneously
appears "inefficient". However, feedforward loops have
the potential to provide temporal control, because expres-
sion of the ultimate target may depend on the accumula-
tion of adequate levels of master regulator and the
secondary regulators [47]. Therefore, if we consider a
sequential gap in the activation time of the target genes
and the miRNA, then this downstream p53-gene and p53-
miR regulation appears coherent. Feedforward loops may
provide a form of multistep ultrasensitivity [48], as any
deviation from the p53's steady state would drive the
downstream targets and miRNA (p53-miR) away from
their steady states in the same direction. p53-miRs could
therefore tune the production rate of the downstream p53
target gene opposite to the direction of p53's fluctuation.
Such noise buffering probably helps to maintain target
Table 1: p53-miRs (microRNAs which have a conserved p53 binding site in their flanking 10 kb genomic sequence) which putatively 
target known transcription factors that are either upstream or downstream to p53 network (based on p53 knowledge base [36]) (A: 
activator; R: Repressor; U: uncharacterized). Only those targets are shown that are predicted as miRNA targets by 2 or more than 
two algorithms. miRNAs that are in bold represent miRNAs induced more than 1.5 fold (p < 0.05) after p53 activation [11]. The last 
column indicates whether a miRNA has been reported in literature as differentially expressed in cancer or cancer cell lines.
miRNA TF TargetScanS miRanda microT miRtarget picTar Relation to p53 
(Interaction Type) 
[20]
Differentially 
expressed in cancer
hsa-miR-183 EGR1 + + - + - Upstream (A) Yes
hsa-miR-26b HOXA5 + - - + - Upstream (A) Yes
hsa-miR-96 HOXA5 + - - + - Upstream (A) Yes
hsa-miR-376a HOXA5 - + + - - Upstream (A) No
hsa-miR-376b HOXA5 - + + - - Upstream (A) No
hsa-miR-181c FOS + + - + - Upstream (A/R) Yes
hsa-miR-222 FOS + + - - - Upstream (A/R) Yes
hsa-miR-101 FOS + + - + - Upstream (A/R) No
hsa-miR-10a BCL6 + + - - - Upstream (R) Yes
hsa-miR-124a KLF4 + - - + - Upstream (R) Yes
hsa-miR-148a KLF4 + + + + - Upstream (R) Yes
hsa-miR-32 KLF4 + + - + - Upstream (R) Yes
hsa-miR-34a KLF4 + - - + - Upstream (R) Yes
hsa-miR-7 KLF4 + - - + - Upstream (R) Yes
hsa-miR-508 KLF4 - + - + - Upstream (R) No
hsa-miR-155 CEBPB + + + - - Upstream (U) Yes
hsa-miR-27a BTG2 + + + - - Downstream (A) Yes
hsa-miR-32 BTG2 + + - - - Downstream (A) Yes
hsa-miR-27a CCNG1 + - - + - Downstream (A) Yes
hsa-miR-122a CCNG1 + + - + - Downstream (A) Yes
hsa-miR-33 EEF1A1 + + - - - Downstream (A) No
hsa-miR-502 GADD45A - + - + - Downstream (A) No
hsa-miR-19b IGFBP3 + + - - - Downstream (A) Yes
hsa-miR-29a MMP2 - + - + - Downstream (A) Yes
hsa-miR-29b MMP2 - + - + - Downstream (A) Yes
hsa-miR-29c MMP2 - + - + - Downstream (A) Yes
hsa-miR-128b PLK2 + + - + + Downstream (A) Yes
hsa-miR-200b PLK2 + + - + - Downstream (A) Yes
hsa-miR-200c PLK2 + + - + - Downstream (A) Yes
hsa-miR-27a PLK2 + + - + + Downstream (A) Yes
hsa-miR-30b SERPINE1 + + + + - Downstream (A) Yes
hsa-miR-30c SERPINE1 + + + + - Downstream (A) Yes
hsa-miR-34a SERPINE1 + - - + - Downstream (A) Yes
hsa-miR-192 RB1 + + - - - Downstream (A/R) Yes
hsa-miR-200b ANLN + + - - - Downstream (R) Yes
hsa-miR-200c ANLN + + - - - Downstream (R) Yes
hsa-miR-142-3p IER3 - + - + - Downstream (R) Yes
hsa-miR-124a SCD + - - + - Downstream (R) YesBMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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Heat map representation of p53-miRs and their target genes relative to the p53 network Figure 2
Heat map representation of p53-miRs and their target genes relative to the p53 network. 115 p53-miRs are predicted to target 
transcription factors that are either p53 regulators (upstream) or p53 targets (downstream) (A).BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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protein homeostasis and ensures more uniform expres-
sion [49] of the p53 downstream target genes within a cell
population. Additionally, since the level of p53-miR
defines the p53 downstream target's translation rate, their
coexpression may allow p53-miR to fine-tune the down-
stream target's steady state. Thus, p53-miRs acting on p53
downstream targets could significantly shorten the
response delay, leading to more effective noise buffering,
as well as precise definition and maintenance of steady
states.
We found two entries in TarBase (database of experimen-
tally validated microRNA target genes) [39] which are rel-
evant and could be interesting to p53 network (a) mir-127
targeting BCL6 [50], an upstream repressor of p53 [51]
(Figure 4B) and (b) mir-106a reported to suppress RB1
[52]. A previous study has shown that mir-106a is induced
more than 1.5 fold (p < 0.05) after p53 activation [11].
p53 is known to suppress RB1 transcription through inhi-
bition of the basal promoter activity [53]. Additionally,
posttranscriptionally, p53 might suppress RB1 further by
inducing mir-106a, a known suppressor of RB1 (Figure
4C).
As a master transcriptional regulator, p53 is also known to
trans-repress genes including those affecting signaling
pathways such as cell proliferation, apoptosis and
cytoskeleton organization [54,55]. Although, the mecha-
nism(s) of repression is often unclear and may not be
dependent on site-specific DNA-binding activity [54-57],
the responsiveness of some genes to p53 can be indirect in
that target genes (transactivated or transrepressed) might
be other transcription factors [55,58] or microRNAs,
which then modulate downstream responses to p53 sign-
aling. We, therefore, hypothesize that in case of p53
downstream targets, the foremost activated positive feed-
back in a coupled feedback circuit can rapidly induce the
"on" state transition of the signaling system (p53 activat-
ing downstream target genes), and that then another
delayed positive feedback (p53 suppressing miRNAs that
target p53 downstream target genes) robustly maintains
this "on" state. Finally, the most delayed negative feed-
back reinstates the system in the original "off " state, pre-
venting any further excessive response specific to the
applied stimulus.
Loss of p53 expression in some tumors has also been
shown to occur through inhibition of transcription of the
p53 gene itself [51,59,60]. For example, mir-31, one of
the p53-miRs predicted to suppress the upstream activator
(YY1) of p53, is reported to be upregulated in colorectal
cancer [61]. Shalgi et al recently reported that the extent of
miR mediated regulation varies extensively among differ-
ent genes, some of which, especially those who serve as
Heat map representation of p53-miRs and their target genes  relative to the p53 network Figure 3
Heat map representation of p53-miRs and their target genes 
relative to the p53 network. Panels A, B, C and D depict p53-
miRs exclusively targeting p53 upstream activators, upstream 
repressors, downstream activators and downstream repres-
sors respectively along with their predicted target transcrip-
tion factors.BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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regulators themselves, are subject to enhanced miRNA-
based silencing [34].
p53-miR target genes – functional over-representation 
analysis
Functional over-representation analysis was performed to
objectively identify biological processes potentially
affected by p53-miR target genes. Specifically, the percent-
age of p53-miR target genes with a given gene ontology
(GO) annotation was compared with the percentage of
whole miRNA-target genes genome-wide with the same
annotation. A significant p value (p < 0.05) indicates that
the observed percentage of p53-miR target genes with a
given annotation could not likely occur by chance given
the frequency of whole miRNA-target genes genome-wide
with the same annotation. MAMI predicted target genes
for the 143 p53-miRs were 12497. We used DAVID [62],
and our in-house developed ToppGene server [63] for the
functional enrichment analysis. Since apoptosis and
growth arrest are common known consequences of p53
activation, we also tested whether p53-miRs tend to target
apoptotic and cell proliferation related genes. Interest-
ingly, the enrichment analysis revealed that while cell
cycle regulation (p = 8.41E-4) was among the top in the
p53-miR targets functional enrichment (p < 0.05), apopto-
sis was not significant. The other significantly enriched
GO terms include transcription, vesicle-mediated trans-
port, intracellular signaling cascade and cellular metabo-
lism (Additional File 4). Interestingly, vesicle-mediated
transport (p = 3.9 E-6) and endocytosis (p = 5.1 E-4) were
specifically enriched in cancer-associated p53-miR target
genes. Abnormal expression or mutation of endocytosis
proteins has been reported in human cancers [64-66]. The
possibility of harnessing the endocytic machinery to can-
cer through miRNAs could offer viable and promising
leads in cancer therapy.
We extended p53-miR target gene functional enrichment
analysis further to identify specific p53-miRs that signifi-
cantly target apoptotic and cell proliferation genes (see
Tables 2 and 3 for a list of top 25 p53-miRs and their target
apoptotic and cell proliferation genes respectively). There
was an overlap of 10 p53-miRs (mir-181c, mir-200a, mir-
200b, mir-19b, mir-101, mir-106a, mir-142-3p, mir-195,
mir-124a and mir-24) between these two groups. Earlier
studies have shown that mir-23 is indeed critical for cell
proliferation [67]. A recent study also implicated mir-23a,
mir-24 and mir-195 in cardiac hypertrophy and reported
that these miRNAs were regulated in response to stress sig-
naling in the heart [68]. The Additional File 4 enlists the
other functional categories significantly enriched within
the putative p53-miR targets. It is to be noted that 18/25
(72%) apoptotic p53-miRs and 22/25 (88%) cell prolifer-
ation p53-miRs have been reported in literature as differ-
entially regulated in various cancerous tissues or cancer
cell lines (see last columns in Tables 2 and 3).
Another interesting model is SIRT1-mir-34a-p53; SIRT1 is
known to inhibit p53-mediated apoptosis by attenuation
of the transcriptional activation potential of p53 primarily
through deacetylation of p53 [69]. Several recent studies
have shown that p53 activates mir-34a. A speculative
model (Figure 4D) therefore is, in normal state mir-34a, a
known p53-miR, suppresses SIRT1  (which is known to
suppress p53) balancing the SIRT1-mediated transcrip-
tional repression of p53. However, during tumorigenesis,
increased levels of SIRT1 will suppress p53 triggering fur-
ther suppression of p53 downstream mir-34a in a feed-
back loop. Examples of such models may have potential
implications for cancer therapy. For example, combining
DNA damage drugs (since p53 is strongly activated in
response to DNA damage), SIRT1-mediated deacetylase
inhibitors, and mir-34a activation (with "agomiR") may
have synergistic effects in cancer therapy for maximally
activating p53.
p53-miR and p53 protein interaction networks
Since the functional state of a protein-protein interaction
network depends on gene expression, a fundamental
question is what relationships exist between protein inter-
action network and gene regulation [70]. Liang and Li in
their recent study of evidence for global correlation
between microRNA repression and protein-protein inter-
actions reported that interacting proteins tend to share
more microRNA target-site types than random pairs [70].
In the current study, using the known p53-interactants, we
calculated the probability of p53-miRs regulating the p53
Schematic representation of p53-miR-mediated models  downstream (A and C) and upstream (B and D) to p53 Figure 4
Schematic representation of p53-miR-mediated models 
downstream (A and C) and upstream (B and D) to p53.BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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interactants. We mined the BioGRID database [71], and
currently there are 141 known interactants of p53. Sur-
prisingly, 114 of these 141 p53-interactants were pre-
dicted to be regulated by p53-miRs and were shown to be
statistically significant (p = 1.41e-21) (see Additional File
5 for details). Using the known data of miRNAs induced
or repressed following p53 activation [11], we further fil-
tered the p53-miRs that could be associated with the p53
interactome. Figures 5 and 6 show the p53 interactome
along with the putative p53-miR regulators that are shown
to be induced or repressed [11] respectively following the
activation of p53.
Conclusion
In conclusion, our bioinformatic-based analysis yielded
several putative regulatory circuits that involve p53 and
microRNAs along with their target genes. Although these
predicted networks need to be experimentally validated to
ascertain a bona fide regulatory relationship, it is still
exciting to speculate that these p53-miRs may be critical to
tumorigenesis through their regulation of the p53 master
regulatory network. We strongly believe that our results
substantially expand the hitherto little known repertoire
of miRNAs in p53 regulatory network. It can be antici-
pated that further characterization of our predicted p53-
miRs and their target genes will improve our understand-
ing of the underlying processes of cancer, tumorigenesis,
and ultimately impact response to therapy.
Methods
Human miRNA genomic analysis
The human miRNAs analyzed in this study (474 in total)
were derived from the miRNA registry release 9.2 (May
2007; Genome Assembly NCBI-36 [72]). The genomic
sequences, including 10 kb flanking sequences 5' and 3'
for each of the miRNAs, were downloaded using Table
Browser from the UCSC Golden Path [73].
Out of a total 474 human miRNAs analyzed, 100 microR-
NAs were part of a cluster (2 or more miRNAs occurring
together on the genome). In all, there were 100 miRNAs
organized into 37 clusters (see Additional Files 6 and 7 for
details). The cluster definitions were based on those
defined by Yu et al [74]. The nearest neighboring gene
information (gene name, distance from the nearest
miRNA, orientation with respect to the host or neighbor-
ing gene) for each of the miRNA was extracted from the
public database RefFlat provided by the UCSC Golden
Path [73].
Screening miRNA genomic sequences for p53 binding sites
The genomic sequences (10 kb flanking region, 5' and 3')
of the 474 human miRNAs were scanned for potential
p53-binding motifs using the p53MH algorithm [22].
Briefly, p53-binds to a specific sequence comprised of two
decamers (RRRCWWGYYY) separated by 0–13 bp [75].
Nearly all established human response element sequences
(REs) have at least one mismatch in this degenerate
sequence [55]. The computer algorithm p53MH identifies
potential p53-binding sites by a scoring system based on
the percentage of similarity to a consensus sequence. We
set the parameter conditions to include the following
restrictions: (i) a p53MH score ≥ 85%, and (ii) the spacer
between the 10-bp motifs is ≤ 4 bp. Although p53 is
known to bind to sites with a spacer as high as 13 bp [75],
for the current analysis we considered 4 bp spacer as the
maximum limit because majority of the validated p53
binding sites are reported to have a spacer less than 4 bp
(see Additional Files 1 and 2 for the putative p53-miR dis-
tribution).
p53 upstream and downstream activators and repressors
The group of TFs that act upstream to p53 either as activa-
tors or repressors and the p53 target genes involved in spe-
cific p53 downstream effects (activator or repressor) were
downloaded from the compiled and curated dataset of the
p53 knowledge-base [36]. We also mined the BioGRID
database [71] for all known p53 interactants.
p53-miR targets
We used MAMI [25] to download the predicted targets for
the p53-miRs. MAMI has a compilation of target predic-
tion tools, DIANA-microT (version 5/05) [26], miRanda
(version 4/06) [8], TargetScanS (version 4/05) [9], miR-
target (version 3/06) [28] and PicTar (version 5/05) [27].
The miRNAs are based on miRs registry version 8.1 (5/
06).
Functional annotation and prioritization of p53-miRs
To annotate the p53-miRs and to identify/prioritize p53-
miRs that might have potential implications in tumorigen-
esis we performed functional enrichment analysis and
also intersected our predictions with cancer-associated
miRNAs. Specifically, we used (a) literature reported dif-
ferentially expressed miRNAs in cancer; (b) miRNAs
reported as induced or repressed following p53 activation;
and (c) miRNA targets that were functionally enriched
with biological processes like apoptosis, cell cycle, etc.
Known tumor suppressor and oncogenic microRNAs
We manually compiled the list of microRNAs that were
reported in literature as differentially expressed (up- or
down-regulated) in various cancers in human (Additional
File 8).
miRNAs induced or repressed following p53 activation
We intersected our predicted p53-miRs with the data from
Tarasov et al [11] to identify potential p53 induced/
repressed miRNAs. Following a genome-wide screen for
microRNAs regulated by the transcription factor encodedBMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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Table 2: Top 25 most significant p53-miRs that target known apoptotic genes (n = 685). 18/25 apoptotic p53-miRs have been reported in 
literature as differentially regulated in various cancerous tissues or cancer cell lines (see last column). The p-values represent the 
probability of a p53-miR targeting an apoptotic gene purely by chance.
miRNA Total Number of 
Predicted Targets
Apoptosis Genes (n = 685) Genes p-value Cancer miRNA
hsa-miR-30b 1054 64 ABL1, ACTN1, ACVR1, ARHGEF6, ATG5, 
BCL2, BCL2L11, BCL6, BDNF, BECN1, BIRC6, 
BNIP3L, CASP3, CLCF1, CUL2, EBAG9, 
ELMO1, FOXO3A, FXR1, GAS2, GCLC, 
HSPA5, IFI16, IFNG, IHPK3, IL1A, JAG2, 
MAGI3, MAL, MAP3K5, MNT, MYBL2, 
NOTCH1, PAK1, PAK7, PAWR, PAX3, 
PDCD10, PDCD5, PIK3R2, PLAGL2, PPP2R1B, 
PRLR, PSEN2, RARG, RASA1, RHOB, RNF7, 
SGK3, SIAH2, SIRT1, SMNDC1, SNCA, 
SOCS3, SON, SOX9, TESK2, TIA1, TIMP3, 
TNFSF9, TP53INP1, UNC5C, UNC5D, VCP
1.50E-12 Yes
hsa-miR-30c 1040 61 ABL1, ACTN1, ACVR1, ARHGEF6, ATG5, 
BCL2, BCL2L11, BCL6, BDNF, BECN1, 
BNIP3L, CASP3, CLCF1, CUL2, EBAG9, 
ELMO1, FOXO3A, FXR1, GAS2, GCLC, 
HSPA5, IFI16, IHPK3, IL1A, JAG2, MAGI3, 
MAL, MAP3K5, MNT, MYBL2, NOTCH1, 
PAK1, PAK7, PAWR, PAX3, PDCD10, PDCD5, 
PIK3R2, PLAGL2, PPP2R1B, PRLR, PSEN2, 
RARG, RASA1, RHOB, RNF7, SGK3, SIAH2, 
SIRT1, SMNDC1, SNCA, SOCS3, SON, SOX9, 
TIA1, TIMP3, TNFSF9, TP53INP1, UNC5C, 
UNC5D, VCP
2.16E-11 Yes
hsa-miR-30d 1034 57 ABL1, ACTN1, ACVR1, ARHGEF6, ATG5, 
BCL2, BCL2L11, BCL6, BDNF, BECN1, 
BNIP3L, CARD8, CASP3, CLCF1, CUL2, 
EBAG9, ELMO1, FOXO3A, FXR1, GAS2, 
HSPA5, IFI16, IHPK3, IL1A, IL31RA, JAG2, 
MAL, MAP3K5, MNT, MYBL2, NOTCH1, 
PAK1, PAK7, PAWR, PAX3, PDCD10, PIK3R2, 
PLAGL2, PPP2R1B, PRLR, PSEN2, RARG, 
RASA1, RHOB, SGK3, SIAH2, SIRT1, 
SMNDC1, SOCS3, SON, SOX9, TIMP3, 
TNFSF9, TP53INP1, UNC5C, UNC5D, VCP
1.03E-09 Yes
hsa-miR-495 389 31 ACTN2, AKT1, ATOH1, AVEN, BAG4, CARD6, 
CASP2, CTNNAL1, DDX41, DIDO1, EEF1E1, 
EIF2AK2, FOXO3A, IAPP, IGFBP3, MTL5, 
NOTCH2, OPA1, PAWR, PDCD10, PHLPP, 
PIM2, RTN4, SGK, SMNDC1, SOX9, 
STK17A, TGFB2, TMEM23, TNFRSF9, 
TXNDC5
2.17E-09 No
hsa-miR-106a 751 44 ACIN1, ACVR1B, APBB2, APP, BCL2L11, 
BCL2L2, BCL6, BIRC4, BNIP2, BTG1, CASP6, 
CASP8, CDKN1A, CFLAR, COL4A3, DAPK2, 
DEDD, DNASE2, DNM2, E2F1, EGLN3, 
EP300, FASTK, FOXL2, HIF1A, INHBA, 
LALBA, MAP3K5, PAK7, PIK3R1, PLAGL2, 
PPARD, PPP2CA, PTEN, PURB, SQSTM1, 
STK17B, TAOK2, TAX1BP1, TIMP3, 
TMEM23, TNFRSF21, TOPORS, TP53INP1
1.54E-08 YesBMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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hsa-miR-124a 1333 62 ACTN4, AHR, AKT1S1, ANXA5, APBB2, 
APPBP1, ARHGDIA, AXIN1, BAG3, BCL2L11, 
BCL6, BECN1, CCL2, CDKN1A, CUL5, 
DHCR24, DNM2, DPF2, ERN1, FXR1, GAS2, 
GLO1, HIP1, HTATIP2, IHPK2, JAG2, LITAF, 
MITF, NR4A1, PDCD10, PDCD6, PEA15, 
PEG3, PIK3CA, PIM1, PLAGL2, PPM1F, 
PPP1R13L, PROC, PURB, RAF1, RARG, 
RASSF5, RFFL, RHOT1, RIPK2, RP6-
213H19.1, SEMA6A, SFRP5, SGK, SGPL1, 
SGPP1, SH3KBP1, SIRT1, SLK, SOX9, SPHK1, 
STK4, TMEM23, TP53INP1, TRIB3, 
ZDHHC16
1.06E-07 Yes
hsa-miR-20b 751 42 ACIN1, ACVR1B, APBB2, APP, BCL2L11, 
BCL2L2, BCL6, BIRC4, BNIP2, BTG1, CASP6, 
CASP8, CASP8AP2, CDKN1A, COL4A3, 
DAPK2, DEDD, DNASE2, DNM2, E2F1, 
EGLN3, EP300, FASTK, FOXL2, HIF1A, IKIP, 
LALBA, MAP3K5, PAK7, PIK3R1, PLAGL2, 
PPP1R13L, PPP2CA, PTEN, PURB, SQSTM1, 
TAOK2, TIMP3, TMEM23, TNFRSF21, 
TOPORS, TP53INP1,
1.18E-07 No
hsa-miR-24 445 30 ACVR1B, ADAMTSL4, ADORA1, BCL2L11, 
BCL2L12, BCL2L2, CARD10, CD28, CDK5, 
CIDEA, CLCF1, CSF2, FASLG, IHPK2, LALBA, 
MNT, PAK7, PCSK9, PEA15, PIM1, PIM2, 
PURB, RARG, RASA1, SPHK1, TMEM23, 
TNFRSF19, TNFRSF1B, TP53INP1, TRAF7,
1.66E-07 Yes
hsa-miR-27a 579 32 ANXA5, AXUD1, BAG2, BIRC4, BNIP3L, 
BTG1, CDK5R1, CFDP1, EI24, FAIM, 
FOXO1A, HIP1, IFNG, IGF1, IL10, JMY, MITF, 
MLH1, NEK6, NGFR, NGFRAP1, PHB, 
PLAGL2, PRKRA, RASSF5, RYBP, SAP30BP, 
SEMA6A, SERINC3, SFRP1, TMEM23, 
ZNF443
4.86E-06 Yes
hsa-miR-195 766 38 ALOX12, APP, ARHGDIA, BAG5, BCAP29, 
BCL2, BCL2L2, BDNF, BFAR, CARD10, CBX4, 
CD28, CD40, CDK5R1, CUL2, DEDD, MNT, 
PAK7, PCBP4, PDCD4, PIM1, PLAGL1, 
PPP2R1A, PTH, PURB, RAD9A, RAF1, RASSF5, 
RIPK2, RYBP, SEMA6A, SGK, SIAH1, SNCA, 
SNRK, SON, UBE4B, ZDHHC16,
8.00E-06 Yes
hsa-miR-182 485 28 ACVR1, ARHGDIA, BAG4, BCL2, BCL2L12, 
BDNF, CFL1, CUL5, ELMO1, EP300, 
FOXO3A, FXR1, MITF, NCKAP1, NPM1, 
PIK3R1, PRKCE, RARG, RASA1, RNF130, 
RRAGA, RTN4, SERPINB2, TMEM23, 
TOPORS, TP53INP1, UNC5D, ZAK
8.50E-06 No
hsa-miR-153 464 27 ACTN4, ACVR1B, APBB2, APP, ATF5, ATG5, 
BCL2, CIB1, FOXO1A, GRIK2, IGF1R, LCK, 
MAP3K7, MITF, POU4F1, PRKAA1, RASA1, 
RTN4, SGK3, SH3KBP1, SIRT1, SNCA, 
SOCS2, SPHK2, TESK2, TIAL1, TP53INP1
1.06E-05 Yes
hsa-miR-200a 634 33 APBB2, ATF5, BAG2, CROP, CUL3, FOXO3A, 
HGF, IL1A, MAL, MAP3K7, MSH2, NME1, 
PAX3, PDCD4, PERP, PHLPP, PLAGL2, 
POU4F1, PPP2CA, PRKCE, SEMA6A, SIAH1, 
SIRT1, SON, STAT5A, STAT5B, TESK2, 
TGFB2, TIAL1, TP53INP1, TXNL1, UBE4B, 
UNC5C
1.20E-05 Yes
hsa-miR-141 413 24 ACVR1B, ALB, APBB2, BAG2, BCL10, DCC, 
EBAG9, FOXO3A, HMGB1, IL1A, NME1, 
PAK1, PDCD4, PERP, PHLPP, PPP2CA, PTK2B, 
SIAH1, SMNDC1, SNCA, SON, STAT5A, 
TGFB2, TP53INP1
3.32E-05 Yes
Table 2: Top 25 most significant p53-miRs that target known apoptotic genes (n = 685). 18/25 apoptotic p53-miRs have been reported in 
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hsa-miR-19b 715 34 ACTN1, BAG5, BCL3, CASP8, CSE1L, CUL5, 
DLX1, FASTK, GULP1, HIF1A, HIP1, IGF1, 
IGFBP3, MAEA, MAP3K1, NGFRAP1, PIK3CA, 
PRKAA1, PTK2B, RAF1, RHOB, RYBP, SGK, 
SGPP1, SLC25A6, SOCS3, SPHK2, SULF1, 
TESK2, TIA1, TIMP3, TNFRSF12A, TP53INP1, 
TP73L
5.53E-05 Yes
hsa-miR-
518e
312 19 ACTN4, ALS2CR2, ANXA5, BNIP3, CD5, 
CDC2L2, DFFB, FGFR1, FXR1, IFNG, MAPK1, 
PIM1, PML, PPP1R13B, RRAGC, SON, TRAIP, 
TRIAP1, VCP
0.000116
642
No
hsa-miR-101 627 30 APP, BAG1, BUB1B, CD28, CDK5R1, CUL3, 
EBAG9, EDAR, EIF2AK3, FOXO1A, ING4, 
MAL, NCR1, NGFRAP1, PAX3, PLAGL1, 
PPP1R13B, PRKAA1, PRKCE, PURA, PURB, 
SEMA6A, SFRP1, SGK, SGPL1, SOCS2, SOX9, 
STAMBP, STK4, TP73L
0.000134
035
No
hsa-miR-183 428 23 AXUD1, BCL6, BNIP3L, BTG1, CD3E, 
CDK5R1, CTSB, DAP, EI24, FOXO1A, LCK, 
NOTCH1, PDCD11, PDCD4, PLAGL2, 
PPP2CA, PRKCA, PSEN2, PURA, RHOB, 
TP53BP2, UNC13B, VDAC1
1.54E-04 Yes
hsa-miR-519c 428 23 ACVR1, ANXA4, AVEN, BAG3, BECN1, 
BIRC6, CAMK1D, DEDD, FASLG, FASTK, 
GLO1, IKIP, INHBA, NFKBIA, PTH, TAX1BP1, 
TEGT, TMEM23, TNFRSF10D, TNFSF18, 
TOPORS, TPT1, VCP
0.000154
374
No
hsa-miR-181c 824 36 AHR, APIP, ASAH2, ATG5, BCL2, BCL2L11, 
BCL6, BCLAF1, CBX4, CCAR1, CEBPG, 
CECR2, CUL3, DNAJA3, GRIK2, HMGB1, 
HSPA5, IL1A, MAEA, MAP3K10, MGMT, 
NOTCH2, PAK7, PAWR, PDCD4, PHLDA1, 
PRKCE, PURB, RAD21, RNF34, SIRT1, SPP1, 
TIMP3, TNFRSF11B, TUBB, UNC5B
1.82E-04 Yes
hsa-miR-107 436 23 AATF, ACVR1, APP, BCL2L2, BDNF, CFL1, 
CIAPIN1, ICEBERG, IHPK3, MAP3K7, NME5, 
NOTCH2, PDCD10, PIK3R1, PRKCE, PTH, 
PURB, RAD21, RASSF5, RYBP, SNRK, THY1, 
VCP
2.02E-04 Yes
hsa-miR-
200b
737 33 ALS2CR2, APBB2, ARHGDIA, BAG2, BCAP29, 
BIRC4, CBX4, CROP, EP300, ERN1, 
FOXO3A, HGF, IL1A, MLH1, MYC, NPM1, 
NTF3, PAK7, PDCD10, PERP, PPM1F, 
PPP2CA, PRKCA, PROK2, RHOT1, SIAH1, 
SLK, STAT5A, SULF1, TIAL1, TNFRSF11B, 
TUBB, TUBB2C
2.15E-04 Yes
hsa-miR-29a 530 26 ANGPTL4, BAK1, BCL2L7P1, CD40, DAXX, 
DPF1, DUSP22, ELMO2, FEM1B, IFNG, 
MCL1, MSH6, MYBL2, POLB, PPP1R13B, 
PPP2CA, PRKRA, PTEN, SGK, TNFRSF1A, 
TNFRSF9, TRAF4, UACA, UBE4B, UNC13B, 
ZNF346
2.51E-04 Yes
hsa-miR-142-
3P
364 20 AKT1S1, BCL2L1, BIRC3, BUB1B, CRTAM, 
FOXO1A, HDAC1, HMGB1, IER3, IL6, PPT1, 
PRKDC, PRLR, PURB, RARG, RNF7, SGK, 
TESK2, TMEM23, TNFSF18
3.05E-04 Yes
hsa-miR-
520h
238 15 ATF5, BRE, CASP6, CDKN2A, CFLAR, 
DNASE2, FASTK, HBXIP, HIF1A, IFT57, 
LALBA, PDIA3, STK17A, TAX1BP1, VHL
0.000412
436
No
Table 2: Top 25 most significant p53-miRs that target known apoptotic genes (n = 685). 18/25 apoptotic p53-miRs have been reported in 
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Table 3: Top 25 most significant p53-miRs that target known cell proliferation genes (n = 712). 22/25 of these have been reported in 
literature as differentially regulated in various cancerous tissues or cancer cell lines (see last column). The p-values represent the 
probability of a p53-miR targeting a cell proliferation gene purely by chance.
miRNA Total Number of 
Predicted Targets
Cell Proliferation 
Genes (n = 712)
Genes p-value Cancer miRNA
hsa-miR-23a 656 44 ALDH1A2, BCL11B, CBFA2T2, CBFA2T3, 
CDC6, CDK5R1, CFDP1, CSE1L, CTNNBIP1, 
CUL3, CXCL5, ELF4, ELF5, EPS15, GPC4, 
HDGFRP3, HOXA3, IHH, IL11, IL6R, IRF2, 
KITLG, LRP5, MAPRE1, MDK, MET, MLLT7, 
NAP1L1, NOTCH2, NPM1, NR6A1, ODZ1, 
OPRM1, PRKRIR, PTK2B, RAP1B, SMAD3, 
SPOCK1, STAT5B, TGFA, TOB2, TRIB1, 
TUSC2, ZAK
8.42E-10 Yes
hsa-miR-92 614 41 ADM, AGGF1, APRIN, BMPR2, BRCA1, BTG2, 
CBFA2T3, CDC27, CDK6, CDKN1C, 
CTNNBIP1, CUL3, CXCL5, DERL2, DLG5, 
EDG1, EPS8, GDF11, HHIP, IGF1R, INSIG1, 
IRS2, KLF4, LBX1, MITF, NCK2, NF1, 
NOTCH1, NOX4, PAFAH1B1, PAX3, PCAF, 
RAP1B, RBM9, SPHK2, TBX3, TCFL5, TOB1, 
TOB2, UTP20, ZAK
3.64E-09 Yes
hsa-miR-32 630 39 ADM, AGGF1, APRIN, BMPR2, BTG2, BTLA, 
CBFA2T3, CDK6, CDKN1C, CHRM5, 
CTNNBIP1, CUL3, CXCL5, EDD1, EDG1, 
EPS8, EVI5, GDF11, HHIP, INSIG1, IRS2, 
KLF4, LBX1, MITF, NCK2, NOTCH1, NOX4, 
PAFAH1B1, PAX3, PCAF, RAP1B, RBM9, 
SPHK2, TBX3, TCFL5, TOB1, TOB2, TTK, 
ZAK
6.67E-08 Yes
hsa-miR-200b 737 42 APRIN, BAP1, BCL11B, BHLHB3, CD274, 
CDC25B, CNOT8, CNTFR, CTBP2, EDNRA, 
EPS8, ETS1, EVI5, GAB1, GLI3, HDAC4, 
HELLS, HGF, IL1A, KHDRBS1, KLF10, KLF4, 
LAMC1, LRP1, LRPAP1, MAFG, MAPRE1, 
MXD4, MYC, NCK2, NDN, NPM1, PCAF, 
POU3F2, PROK2, PTHLH, RAP1B, SESN1, 
SHC1, STAT5A, SUZ12, TOB1
2.02E-07 Yes
hsa-miR-200c 751 42 APRIN, BAP1, BCL11B, BHLHB3, BIN1, 
CD274, CNOT8, CNTFR, CTBP2, EDNRA, 
EPS8, ETS1, EVI5, GAB1, GLI3, GNAT1, 
HDAC4, HELLS, HGF, KHDRBS1, KLF10, 
KLF4, LAMC1, LRP1, LRPAP1, MAFG, 
MAPRE1, MXD4, MYC, NCK2, NDN, NPM1, 
PCAF, POU3F2, PROK2, PTHLH, RAP1B, 
SCG2, SESN1, SHC1, STAT5A, TOB1
3.33E-07 Yes
hsa-miR-195 766 42 ALOX12, AXIN2, BAI1, BDNF, BHLHB3, 
BIN1, BTG2, CBFA2T3, CD164, CD28, 
CD40, CDC25A, CDC27, CDK5R1, CHEK1, 
CUL2, DNAJA2, EFNB1, FGF2, FGF7, FOSL1, 
HDGF, HOXA3, LAMC1, MAPRE1, MNT, 
MTCP1, NF2, PAFAH1B1, PDAP1, PIM1, 
POU3F2, PPAP2A, PPM1D, PRDM4, PRKCD, 
PTHLH, PURB, RAF1, RARRES1, SESN1, 
SPEG
5.60E-07 Yes
hsa-miR-10a 230 20 BCAR1, BCL6, BDNF, CDK4, CTNNBIP1, 
FLT1, HDAC4, HOXA3, ID4, IFNAR2, 
JARID2, KLF11, KLF4, MAPRE1, PAFAH1B1, 
PURB, SERTAD1, SHC1, TRAIP, ZMYND11
7.09E-07 Yes
hsa-miR-10b 237 20 BCAR1, BCL6, BDNF, CDK4, CNOT8, 
CTNNBIP1, FLT1, HDAC4, HOXA3, ID4, 
IFNAR2, JARID2, KLF11, KLF4, MAPRE1, 
PAFAH1B1, PURB, SHC1, TRAIP, ZMYND11
1.14E-06 YesBMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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hsa-miR-24 445 29 ADM, CD164, CD28, CDK5, CDKN1B, 
CDV3, CNTFR, CSF2, CSK, DCTN2, EDG1, 
FLT1, GPC4, ING5, INSIG1, MAFG, MNT, 
MXI1, NUDC, PDGFRA, PIM1, PIM2, PURB, 
RAP1B, SERTAD1, SESN1, SPHK1, TOB2, 
ZNF259
1.16E-06 Yes
hsa-miR-203 505 31 ALDH1A2, BCL11B, CASP3, CNTFR, DLG5, 
EDD1, EDN1, EDNRA, FGG, GLI3, HBEGF, 
ID4, INSIG1, IRS2, KHDRBS1, MAPRE1, 
NUMBL, PDAP1, PDGFRA, PPM1D, PRKRIR, 
PURB, RERG, SMAD1, SMAD3, TBX3, 
TGFB2, TNFRSF8, TUSC2, USP8, ZMYND11
1.77E-06 Yes
hsa-miR-124a 1333 60 ANXA7, AR, BCL11B, BCL6, BTG2, CAPN1, 
CAV1, CD164, CD276, CDK6, CDKN1A, 
CUL5, DLG5, DLG7, EFNB1, EMP2, EPS8, 
ERF, ETS1, EVI1, EVI5, FGFR1OP, GAS1, 
GNAI2, GPC4, HDAC4, IL9R, ING1, JAG1, 
JAG2, KLF4, LAMC1, MAP3K11, MAPRE1, 
MDK, MITF, MXD4, NCK2, NRP1, OVOL2, 
PAFAH1B1, PBEF1, PDZK1, PGF, PIM1, 
PRKD1, PTHLH, PURB, QSCN6, RAF1, 
RAP1B, RARRES1, RHOG, SHC1, SOX9, 
SPHK1, SPOCK1, TAL1, TOB2, UHRF1
1.82E-06 Yes
hsa-miR-106a 751 40 BCL11B, BCL6, BHLHB3, BMPR2, BTG1, 
BTG2, BTG3, CDKN1A, COL4A3, CSF1, 
DERL2, E2F1, EBI3, EDD1, EDG1, EFNB1, 
EREG, FLT1, FZD3, GAB1, HDAC4, KLF11, 
LIF, MAP3K11, MAPRE1, PAFAH1B1, PCAF, 
PDGFRA, PPARD, PTEN, PTHLH, PURB, RB1, 
RBBP7, TAL1, TBX3, TGFB1, TOPORS, 
TSG101, TUSC2,
2.13E-06 Yes
hsa-miR-142-3P 364 25 BTG4, BUB1B, CDC14A, CDC25C, CRTAM, 
EDG3, EHF, ERG, FGFR1OP, FNTB, FOXO1A, 
FRK, GRN, IL6, IL6ST, KHDRBS1, KLF10, 
MAP3K11, MLLT7, NUMBL, PCAF, PURB, 
SKP2, TNFRSF13C, UTP20,
2.50E-06 Yes
hsa-miR-33 312 22 APRIN, BCL11B, BMPR2, CD40, CDK6, 
CKS2, DOCK2, FGA, FGFBP1, HIPK2, 
HOXC10, IRS2, LGI1, LMO1, NPM1, NPY, 
PDGFRA, PIM1, PURB, RB1, TSG101, 
UBE2V2,
6.53E-06 No
hsa-miR-372 378 24 BCL6, BTG1, CDCA7, CDK2, CXCR4, DERL2, 
DNAJA2, E2F1, ERBB4, FGF9, FRK, IRF2, 
MAP3K11, MNT, PCAF, PRDM4, PURB, 
RBBP7, TAL1, TOB2, TUSC2, UCHL1, 
ZFP36L2, ZMYND11,
1.47E-05 Yes
hsa-miR-101 627 33 BUB1B, CALCRL, CBFA2T2, CD28, CDC14A, 
CDC27, CDH5, CDK5R1, CDK6, CSRP2, 
CUL3, DLG5, ELN, EMP1, FGA, FOXO1A, 
GLI3, GNB1, ING4, PAX3, PBEF1, PPBP, 
PPP1R8, PURA, PURB, RAP1B, RBBP7, SOX9, 
STAMBP, TAL1, TCF19, TGFBR1, TRIB1,
2.09E-05 No
hsa-miR-19b 715 36 ANXA7, BMPR2, CD164, CDC2L5, CHERP, 
CLK1, CNTFR, CSE1L, CUL5, DLG5, DNAJA2, 
EDG1, EPS15, ERBB4, EREG, FOSL1, GCG, 
GRN, HDAC4, HHIP, HPRT1, ID4, IGF1, 
IMPDH1, KLF10, LIF, PCAF, POU3F2, PTK2B, 
RAF1, RAP1B, SMARCA2, SPHK2, ST8SIA1, 
SUZ12, ZMYND11
2.29E-05 Yes
hsa-miR-196a 243 18 ACSL6, ANXA1, ATP6AP1, CASP3, CBFA2T3, 
CCL23, CDKN1B, ELF4, ERG, IGFBP7, ING5, 
MYC, NFKBIA, PA2G4, PDGFRA, SSR1, 
UHRF2, ZMYND11
2.30E-05 Yes
Table 3: Top 25 most significant p53-miRs that target known cell proliferation genes (n = 712). 22/25 of these have been reported in 
literature as differentially regulated in various cancerous tissues or cancer cell lines (see last column). The p-values represent the 
probability of a p53-miR targeting a cell proliferation gene purely by chance. (Continued)BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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hsa-miR-26b 633 33 ADM, BCL6, BTG1, CDC27, CDC2L5, CDK6, 
CKS2, DLG5, DNAJA2, ENPEP, EPS15, 
ERBB4, HGF, HIPK2, HOXD13, IGF1, IL6, 
JAG1, KLF10, KLF4, LIF, MITF, MXI1, PAWR, 
PBEF1, PDGFRA, PIM1, PRKCD, PRKCQ, 
PTEN, SMAD1, SMAD4, TOB1,
2.52E-05 Yes
hsa-miR-196b 245 18 ACSL6, ANXA1, ATP6AP1, CBFA2T3, CCL23, 
CDKN1B, ELF4, ERG, FOXN1, IGFBP7, ING5, 
MYC, NF2, NFKBIA, PA2G4, PDGFRA, SSR1, 
ZMYND11
2.57E-05 Yes
hsa-miR-9 737 36 ARHGEF2, BCL6, BIN1, BTG2, CBFA2T2, 
CNTFR, COL18A1, CUL4A, CXCR4, EDD1, 
ERG, ETS1, FGF5, FOXO1A, HDAC4, HES1, 
ID4, INSIG1, KITLG, LEPRE1, LIFR, NAP1L1, 
NOTCH2, NOX4, NRP1, ODZ1, PDGFC, 
PMP22, POU3F2, PPARD, RAP1B, RBM9, 
SHC1, TBC1D8, TGFBI, UHRF1
4.29E-05 Yes
hsa-miR-29b 541 29 BAX, BCL11B, CAV2, CD40, CDC7, CREG1, 
DUSP22, EPS15, FRAT2, FSCN1, GAB1, 
HDAC4, INSIG1, JARID2, LAMC1, MAFG, 
NASP, PDGFB, PDGFC, PINX1, PMP22, 
PPM1D, PRKRA, PTEN, SETDB1, SMARCA2, 
SPEG, TNFRSF9, UHRF2
4.71E-05 Yes
hsa-miR-200a 634 32 APRIN, ATP8A2, BAP1, BIN1, CD274, 
CDC14A, CDC25A, CDC25B, CDC2L5, 
CDK6, CSF3, CTBP2, CTNNB1, CUL3, FLT1, 
GAB1, HDAC4, HGF, IL1A, IRS2, JAG1, 
NME1, NRP1, PAX3, PBEF1, POU3F2, 
PRKD1, SCG2, STAT4, STAT5A, STAT5B, 
TGFB2
6.15E-05 Yes
hsa-miR-34a 666 33 AREG, ARX, BCL11B, BCL6, CBFA2T3, CD28, 
CD3E, CDC25A, CSF1R, EFNB1, ENPP7, 
FOSL1, GFER, GNAI2, IL6R, JAG1, KITLG, 
KLF4, LGI1, MET, MOV10L1, NOTCH1, 
NOTCH2, NUMBL, PDGFRA, PGF, PRKD1, 
PURB, SPEG, TGFBI, TOB2, TOPORS, UHRF2
6.76E-05 Yes
hsa-miR-181c 824 38 ABI1, ADAMTS1, ADM, ARHGEF2, BCL6, 
BMPR2, CALCRL, CBFA2T2, CBFA2T3, 
CKS1B, CUL3, EDG1, EPS15, ERF, ERG, 
ETS1, FLT1, IL1A, IRS2, LIF, LMO1, 
NOTCH2, NR6A1, PAFAH1B1, PAWR, PCAF, 
PDAP1, PDGFRA, PRDM4, PRKCD, PURB, 
RAP1B, RBBP7, TGFBI, TGFBR1, TGFBR2, 
USP8, VIP
8.89E-05 Yes
Table 3: Top 25 most significant p53-miRs that target known cell proliferation genes (n = 712). 22/25 of these have been reported in 
literature as differentially regulated in various cancerous tissues or cancer cell lines (see last column). The p-values represent the 
probability of a p53-miR targeting a cell proliferation gene purely by chance. (Continued)BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
Page 15 of 19
(page number not for citation purposes)
by the p53 tumor suppressor gene, the authors reported
that after p53-activation the abundance of thirty-four
miRNAs was significantly increased, whereas sixteen miR-
NAs were suppressed [11].
p53-miR target genes – Functional enrichment
Functional over-representation analysis was performed to
objectively identify biological processes potentially
affected by p53-miR target genes. Specifically, the percent-
age of p53-miR target genes with a given gene ontology
(GO) or pathway annotation was compared with the per-
centage of all miRNA-target genes genome-wide with the
same annotation. A significant p value (p < 0.05) indicates
that the observed percentage of p53-miR target genes with
a given annotation could not likely occur by chance given
the frequency of miRNA-target genes genome-wide with
the same annotation. For functional enrichment analysis,
we used DAVID [62] and ToppGene [63].
p53-miR and p53-interactant gene networks
p53-miR and p53-interactant gene networks were gener-
ated using aiSee [76] with force-directed layouts. The GDL
(Graphics Description Language) files, generated by a
locally-implemented  JAVA  GDL library, were used as
input to aiSee to create SVG (Scalable Vector Graphics)
network graphs. The p53-related interactions were down-
loaded from BioGRID [71].
p53 interactome along with the putative miR regulators that are shown to be induced following the activation of p53 [11] Figure 5
p53 interactome along with the putative miR regulators that are shown to be induced following the activation of p53 [11]. miR-
NAs are represented by yellow ellipses, target genes are represented by green boxes. p53 is represented in the center as blue 
circle. Induction of the miRNAs by p53 is represented by directed red lines. Negative regulation of the target genes by miRNAs 
are represented by dark grey lines. The protein interactions are represented by undirected light blue lines. Networks (using 
force-directed layouts) were generated using aiSee [76] network visualization software.BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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Statistical methods
Fisher's exact test was used to calculate a p-value estimat-
ing the probability that a particular category of miRNAs is
associated with a particular pattern or cluster of miRs
more than would be expected by chance. Fisher's exact test
was performed online at the MATFORSK [77]. For testing
the functional enrichment of p53-miR  target genes,
DAVID [62] and ToppGene server [63] were used. For sta-
tistical analysis, the programming language and statistical
environment R [78] were used.
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Additional File 1
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Click here for file
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p53 interactome along with the putative miR regulators that are shown to be repressed following the activation of p53 [11] Figure 6
p53 interactome along with the putative miR regulators that are shown to be repressed following the activation of p53 [11]. 
miRNAs are represented by yellow ellipses, target genes are represented by green boxes. p53 is represented in the center as 
blue circle. Induction of the miRNAs by p53 is represented by directed red lines. Negative regulation of the target genes by 
miRNAs are represented by dark grey lines. The protein interactions are represented by undirected light blue lines. Networks 
(using force-directed layouts) were generated using aiSee [76] network visualization software.BMC Genomics 2008, 9:88 http://www.biomedcentral.com/1471-2164/9/88
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